Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Extension Study of IMVT-1402 in Adults With Graves' Disease
2025-524001-33-00Phase 2Authorised
- Sponsor
- Immunovant, Inc.
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 22
01
Overview
Phase 2 trial of IMVT-1402 in Graves' disease (3 arms), sponsored by Immunovant, Inc. Planned start Jun 2026; status: authorised.
02
Drugs
IMVT-1402
03
Conditions
Graves' disease
Beyond the preview
Go deeper on 2025-524001-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524001-33-00.